Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer’s disease: a systematic review and meta-analysis

被引：0
作者：
Julyana M. Dantas
Antonio Mutarelli
Denilsa D. P. Navalha
Caroline S. Dagostin
Pedro H. C. L. Romeiro
Nicole Felix
Alleh Nogueira
Sávio Batista
Larissa Teixeira
Paulo Caramelli
机构：
[1] Universidade Federal do Rio Grande do Norte,Behavioral and Cognitive Neurology Unit, Faculdade de Medicina
[2] Universidade Federal de Minas Gerais,undefined
[3] Universidade Eduardo Mondlane,undefined
[4] Universidade do Extremo Sul Catarinense,undefined
[5] Centro Universitário de Maceió,undefined
[6] Universidade Federal de Campina Grande,undefined
[7] Escola Bahiana de Medicina e Saúde Pública,undefined
[8] Universidade Federal do Rio de Janeiro,undefined
[9] Universidade Federal de Minas Gerais,undefined
来源：
Neurological Sciences | 2024年 / 45卷
关键词：
Alzheimer disease; Mild cognitive impairment; Monoclonal antibodies; Therapeutic; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2461 / 2469
页数：8
相关论文
共 81 条
  • [1] Tahami Monfared AA(2022)Alzheimer’s disease: epidemiology and clinical progression Neurol Ther 11 553-569
  • [2] Byrnes MJ(2019)The neuropathological diagnosis of Alzheimer’s disease Mol Neurodegener 14 32-8
  • [3] White LA(2017)Mechanisms of Alzheimer’s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, Tau Protein and Other Risk Factors Clin Psychopharmacol Neurosci 15 1-405
  • [4] Zhang Q(2015)Neuroinflammation in Alzheimer’s disease Lancet Neurol 14 388-265
  • [5] DeTure MA(2009)Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies Acta Psychiatr Scand 119 252-162
  • [6] Dickson DW(2006)Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants Int Psychogeriatr 18 151-818
  • [7] Kocahan S(2001)Prevalence, costs, and treatment of Alzheimer’s disease and related dementia: a managed care perspective Am J Manag Care 7 809-62
  • [8] Doğan Z(2013)The economics of mild cognitive impairment Alzheimers Dement 9 58-88
  • [9] Heneka MT(2019)A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease Nat Rev Neurol 15 73-1694
  • [10] Carson MJ(2017)A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease Alzheimers Res Ther 9 95-1030
123456789